A new Cleveland Clinic study documents the impacts that shortages of the immunotherapy agent Bacillus Calmette-Guerin have had on clinical management of non-muscle invasive bladder cancer. Urologic oncologist Robert Abouassaly, MD, discusses the findings and implications.
Investigators tested the idea that SCBC tumors express a unique molecular signature that may distinguish SCBC from other, similar diseases, and that more importantly could point toward better biomarkers and therapies.
Recruitment underway to bring additional leading scientists to expanding GU cancer research program at Cleveland Clinic.
Urologists develop novel evidence-based hospital quality scoring system, the Bladder Cancer Quality Score (BC-QS). They hope it serves as a foundation for continued efforts to improve surgical quality measurement and outcomes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Radical cystectomy patients faced long hospital stays and complications that could lead to readmissions. Cleveland Clinic has overhauled perioperative management, and decreased lengths of stay, readmissions, postsurgery ED visits – and costs. Research is ongoing.
Investigators evaluate the genetics and pathological characteristics of Cleveland Clinic’s cohort of samples to learn more about small cell bladder cancer.
Cleveland Clinic urologic oncologist and researcher Byron Lee, MD, PhD, has received two significant awards recognizing his research in chromatin modifier genes and bladder cancer: a Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research and a Young Investigator Award from the Bladder Cancer Advocacy Network.
Robotic-assisted cystectomy and intracorporeal neobladder formation is performed at select centers. In this video, Glickman Urological & Kidney Institute surgeons demonstrate maneuvers used for a challenging urethro-ileal anastomoses.
Better understanding of chromatin modifier mutations, a hallmark of urothelial bladder cancer, could help researchers design novel therapeutic combinations.
Standard of care for muscle-invasive bladder cancer is cisplatin-based combination neoadjuvant chemotherapy (NAC) then radical cystectomy and lymph node dissection. This article reviews how NAC reduces the risk for recurrence.